PA
Perceptive Advisors
Activity from announced rounds
Activity in this selectionOct 20, 2026 · Sep 21, 2026
Perceptive Advisors is the healthcare investment manager named in Superluminal’s financing and retained company records.
Recorded funding activity
Superluminal develops small-molecule medicines using structural and experimental methods. Vaderis develops an oral treatment for hereditary hemorrhagic telangiectasia, while Imperative develops thromboembolic interventions. The manager remains separate from the Xontogeny venture arm.
- Rounds participated in
- 0
- Confirmed lead rounds
- — All roles disclosed
- New companies
- 0 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share
By stage
No activity in this selection.
By primary sector
No activity in this selection.
By country
No activity in this selection.
Rounds
0 in this selectionNo rounds match this selection.